Is Travere Therapeutics, Inc. (TVTX) a Peter Lynch Stock?
Strong GARP candidate - growth at a reasonable price.
2/6 criteria passed
+2 sector-quality lift. Top-quintile within its sector on 1 of 5 quality metrics. Raw pillar score 73 → lifted to 75 before grade derivation.
Capped from B to C. Share count growing >5%/year - per-share growth eaten by dilution (kills Lynch's whole thesis); Net debt over 5x EBITDA - too leveraged to sustain growth investments What are deal-breaker caps?
Peter Lynch's Criteria, Applied to TVTX
PEG ≤ 1.0
EPS CAGR ≥ 15%
Revenue CAGR ≥ 10%
Net margin > 0
Manageable debt (D/E < 1)
Positive free cash flow
How TVTX Scores on Other Strategies
Live Financial Snapshot
Market cap
$5.33B
P/E (TTM)
-
ROIC (TTM)
-13.09%
Gross margin
93.95%
Other Peter Lynch fit reports
Frequently Asked Questions
What is TVTX's Peter Lynch fit score?
Does Peter Lynch actually own TVTX?
How often is this score updated?
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends TVTX.